Publicacións en colaboración con investigadores/as de Duke University (9)

2024

  1. Effect of sodium–glucose co-transporter-2 inhibitors on survival free of organ support in patients hospitalised for COVID-19 (ACTIV-4a): a pragmatic, multicentre, open-label, randomised, controlled, platform trial

    The Lancet Diabetes and Endocrinology, Vol. 12, Núm. 10, pp. 725-734

  2. Factors Associated With Coronary Angiography Performed Within 6 Months of Randomization to the Conservative Strategy in the ISCHEMIA Trial

    Circulation: Cardiovascular Interventions, Vol. 17, Núm. 6, pp. 457-473

2019

  1. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

    The Lancet Diabetes and Endocrinology, Vol. 7, Núm. 8, pp. 618-628

2018

  1. Alirocumab and cardiovascular outcomes after acute coronary syndrome

    New England Journal of Medicine, Vol. 379, Núm. 22, pp. 2097-2107

2017

  1. Improved risk stratification of patients with atrial fibrillation: An integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation

    BMJ Open, Vol. 7, Núm. 12

2015

  1. Cause of death and predictors of all-cause mortality in anticoagulated patients with nonvalvular atrial fibrillation: Data from ROCKET AF

    Journal of the American Heart Association, Vol. 5, Núm. 3

2006

  1. Periannular Complications in Infective Endocarditis Involving Native Aortic Valves

    American Journal of Cardiology, Vol. 98, Núm. 9, pp. 1254-1260

  2. Periannular Complications in Infective Endocarditis Involving Prosthetic Aortic Valves

    American Journal of Cardiology, Vol. 98, Núm. 9, pp. 1261-1268

2005

  1. Aorto-cavitary fistulous tract formation in infective endocarditis: Clinical and echocardiographic features of 76 cases and risk factors for mortality

    European Heart Journal, Vol. 26, Núm. 3, pp. 288-297